Vistagen Therapeutics:法西地诺重复给药展现与单次给药相当的安全性及耐受性

美股速递
Aug 06

Vistagen Therapeutics 公司宣布,其核心药物法西地诺(Fasedienol)在重复给药试验中,表现出与单次给药同样良好的安全性与耐受性。这一发现,为这款候选药物的后续开发提供了关键性支持。无论是单次应用还是多次给药,法西地诺均未引发显著差异的不良反应,其耐受性特征保持高度一致。这意味着,在反复用药的场景下,该药物的安全性轮廓并未出现意料之外的恶化。对于Vistagen Therapeutics而言,这无疑是一个积极信号。它进一步巩固了法西地诺作为一种潜在治疗选择的地位,特别是在那些需要长期或周期性用药的适应症领域。目前,公司正基于这些数据,积极推进后续的临床研究计划。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10